Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Thomas Ryskamp"'
Autor:
Thomas Ryskamp, Roland A. Newman
Therapeutic antibodies have been on a roller coaster ride of expectation and disappointment. In the early days of murine monoclonal antibody (MAb) production, the image and potential of the “magic bullet” appeared very alluring. The harsh realiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fafe38117a9f1a353e0f623270f64c25
https://doi.org/10.1201/9781482283617-1
https://doi.org/10.1201/9781482283617-1
Autor:
Gene Menendez, Christine A. White, Peter S. Conti, Jacqueline Aussie, P. Foster, Thomas Ryskamp, V. Douglas Harrough, Dan Matso, Peter C. Pieslor
Publikováno v:
Blood. 104:4570-4570
Background: The yttrium 90 (90Y) ibritumomab tiuxetan (ZevalinÒ) therapeutic regimen consists of rituximab 250 mg/m2 on day 1 and 8, followed by indium 111 (111In) ibritumomab tiuxetan for imaging on Day 1 and 90Y ibritumomab tiuxetan for therapy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d54a84e0719db210a78b417e3bad4560
https://doi.org/10.1182/blood.v104.11.4570.4570
https://doi.org/10.1182/blood.v104.11.4570.4570
